Gilead Rises, Boosts Market As Remdesivir COVID-19 Trial Meets Primary Target
April 29, 2020 at 13:12 PM EDT
Wells Fargo does not see a significant commercial opportunity for remdivisir given likely free drug supply.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|